CardioVascular and Interventional Radiology (CVIR) is an official journal of
the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Founded in 1978 by Professors Herbert L. Abrams and Eberhard Zeitler,
CVIR is the longest-running journal in the field of vascular and interventional radiology.
CIRSE Members have unlimited online access to all CVIR articles. To access the full text articles, log in with the credentials for myCIRSE.*
* Please note Chrome users are currently experiencing problems accessing CVIR. If you experience access problems, we recommend first trying another browser (Mozilla Firefox, Edge, Internet Explorer, Safari etc.). Springer is looking into solving the issue. Thank you for your understanding.
Are you attending ET?
Then don't miss what CVIR has prepared for you!
Get a chance to ask the CVIR Editors for some tips and trick on how to get your paper published. Meet the Editorial Office and ask any journal related questions that you might have. Or simply
come to our booth and read the latest articles at our terminal.
See you in Nice!
For more information click here!
Attending ET 2022 in Nice?
Visit the CVIR Endovascular booth on June 22-24 to meet some of the journal's editorial board members and editor-in-chief.
We will also have daily trivia with the chance to win a grand prize, so check out the website and our social media channels each day!
The newest special section of CVIR, covers one of the most challenging interventional radiology procedures, i.e. transjugular intrahepatic portosystemic shunt (TIPS), written by renowned international voices in the field.
This collection of articles was curated by guest editor Dr. Tiago Bilhim.
Make sure to read the article by clicking here.
CIRSE Standards of Practice on Bronchial Artery Embolisation
by Joachim Kettenbach, Harald Ittrich, Jean Yves Gaubert, Bernhard Gebauer & Jan Albert Vos
The added value of RFA for HCC! Retrospective single centre study on 175 patients confirmed that the combination RFA with TACE and a novel tyrosine kinase inhibitor offers improved oncological outcomes for intermediate stage HCC than TACE alone or even TACE and TKI.
Are you about to submit your paper to CVIR?
Click here to find out which biological/biomedical reporting checklists are mandatory when submitting to CVIR.
2020 wasn’t all bad news – CVIR’s impact factor rose from 2.034 in 2019 to an impressive 2.740!
We are proud to host such high-quality articles and tenacious authors, and this new metric indicates that our readership appreciates it too.
Thank you all for making CVIR your IR journal of choice!